Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Prep: Cook: Serves:

Tekes, the Finnish Funding Agency for Innovation, has granted a €2,903,000 loan to Herantis Pharma Plc to support its clinical study of CDNF for the treatment of Parkinson’s disease. The loan was granted conditionally, subject to obtaining regulatory approval for the clinical study.

Pekka Simula, CEO of Herantis Pharma, added: “We are very excited about our opportunity to translate the results of years of leading academic research to clinical stage, hopefully for the benefit of as many patients as possible.”

Herantis aims to start its clinical development programme with regulatory submissions in Finland and Sweden by the end of 2015. Patient treatments are expected to begin in the first half of 2016. The company expects to recruit 18 patients with Parkinson’s disease in this first-in-human study of CDNF.

Last Month

Next Month

Go Back

Share this story

Comments

Carers' Corner

New survey highlights challenges facing Parkinson’s carers

The EPDA launches a new multilingual survey for Parkinson’s carers

Tremor-reducing GyroGlove set to launch in 2017

Volunteer testers wanted as launch date nears

Parkinson’s in the news: March

A roundup of the Parkinson’s news stories in March

Study suggests why neurons die in Parkinson’s disease

Researchers at the University of Córdoba, Spain, have discovered how a certain protein may be linked to death of dopamine-producing neurons associated with Parkinson’s. Using animal models of the condition to conduct their study, the team focused on the protein DJ-1 – whose link to Parkinson’s has previously been established, though its exact function was uncertain. The researchers compared neurons in the brains of mice that possessed the gene expressing DJ-1 with those that did not. The findings revealed that dysfunction or absence of the gene expressing the DJ-1 protein could trigger the ‘cell cycle’ (the process by which cells divide), which should not occur under normal conditions. Because neurons lack the capacity to divide, this causes them die – leading to the onset of symptoms linked with Parkinson’s. It is hoped that uncovering these details about the relationship between DJ-1’s absence and Parkinson’s may lead to the development of…

Researchers have finally identified brain cells linked to Parkinson’s disease

For decades, scientists have known that Parkinson’s is associated with the death of dopamine-producing cells in the brain. Now, researchers from the Broad Institute of MIT and Harvard, US, have discovered the specific subtype of brain cells that die in Parkinson’s disease. Using a technique called single-cell RNA signalling, which enables the individual analysis of cells within a tissue for activity and protein production, researchers identified 10 subtypes of dopamine-producing cells within the donated brains of people who died from causes unrelated to Parkinson’s. The team carried out the same investigation on people who had died with Parkinson’s or a condition with similar symptoms called Lewy body dementia. They discovered that only one subtype of the cells had reduced in number – which suggests many of these cells had died while the people were living. It is hoped that the findings could lead to better understanding of Parkinson’s causes and…

Tiny DBS implant shows potential to advance Parkinson’s disease treatment

In an innovative trial by North Bristol NHS Trust, UK, surgeons have succeeded in implanting a tiny deep brain stimulation (DBS) device into a person’s skull. Their aim? To address symptoms of Parkinson’s. Designed with a tiny battery system that is inserted into the skull, the DBS device delivers electric impulses to targeted areas of the brain through electric probes. In doing so, it works to address abnormal brain cell activity associated with Parkinson’s – and may help to ease symptoms. One of around 25 patients selected for the year-long trial has described the device’s impact as “amazing”. Commenting on the results of the trial so far, consultant neurologist Dr Alan Whone of North Bristol NHS Trust said: “We are hopeful that if these findings hold up, we will have a significant technical advance by which to improve Parkinson’s care across the world.”

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Name
This field is for validation purposes and should be left unchanged.

Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Carers' Corner

New survey highlights challenges facing Parkinson’s carers

Advances

Tremor-reducing GyroGlove set to launch in 2017

Global update

Parkinson’s in the news: March

Study suggests why neurons die in Parkinson’s disease

Researchers have finally identified brain cells linked to Parkinson’s disease

Tiny DBS implant shows potential to advance Parkinson’s disease treatment

{title}

Subscribe

Herantis Pharma granted almost €3 million government loan for Parkinson’s study

News

Author: Parkinson's Life editorsPublished: 15 August 2015

Last Month

Next Month

Share this story

Comments

Related articles

Carers' Corner

New survey highlights challenges facing Parkinson’s carers

Advances

Tremor-reducing GyroGlove set to launch in 2017

Global update

Parkinson’s in the news: March

Study suggests why neurons die in Parkinson’s disease

Researchers have finally identified brain cells linked to Parkinson’s disease

Tiny DBS implant shows potential to advance Parkinson’s disease treatment

{title}

Subscribe

Sign in